Florentin Lukas Holzem
ESR 11: Integrating in vitro dissolution-permeation data with biopharmaceutical models to predict the in vivo performance of drug formulations
Supervisor: Anette Bauer-Brandl
Planned secondments: Roche (Purpose: Formulation manufacturing; in vitro characterization; in silico modelling) NKUA (Purpose: Evaluation of alternative in vitro model (BioGIT)
The aim of the project is to benchmark a range of in vitro dissolution/permeation methods using a variety of enabling formulations. Moreover, an approach for the integration of in vitro dissolution/permeation data with in silico PBPK models will be developed and resulting predictions will be verified by comparison with in vivo reference data. Based on this project, a new guide on optimal selection of in vitro dissolution-permeation methods and in silico tools during formulation development of poorly soluble drugs should be developed.
Florentin Lukas Holzem (ESR 11) is a licenced pharmacist and holds a diploma in Pharmacy and a bachelor’s degree in biology from the University of Greifswald. Early in his pharmacy studies, Florentin was able to gain experience in the field of pharmaceutical technology and biopharmacy by working as a scientific assistant. Based on this interest, he decided to matriculate to the diploma program to gain further knowledge in biopharmaceutics and to strengthen his scientific skills.
During his Diploma thesis at Roche, Florentin was able to get insights into the pharmaceutical industry where he performed biopharmaceutical characterizations and physiologically-based pharmacokinetic modeling (PBPK) of supersaturating formulations.
His research project in the InPharma consortium will focus on different Dissolution-Permeation tools and the integration of resulting data with biopharmaceutical models. He is matriculated at the University of Southern Denmark (SDU) and will spend half of his PhD studies at Roche in Basel.
Florentin Holzem, one of our Early Stage Researchers has published the first InPharma publication as lead author in the European Journal of Pharmaceutical Sciences. The